Join to View Full Profile
300 George StNew Haven, CT 06510
Phone+1 410-299-1044
Dr. Lustberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2009
University of MarylandResidency, Internal Medicine, 2003 - 2006
University of Maryland School of MedicineClass of 2003
Certifications & Licensure
CT State Medical License 2021 - 2025
OH State Medical License 2007 - 2022
MD State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsPatient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.Erica L Mayer, Mary Lou Smith, Annie Guérin, Dominick Latremouille-Viau, Nisha C Hazra
Breast Cancer Research and Treatment. 2025-05-01 - Association of sexual pain and psychological factors among gynecologic and breast cancer patients: application of components of the fear-avoidance model of chronic pain.Lora L Black, Katherine Conroy, Maryam Lustberg, Ritu Salani, Barbara L Andersen
Journal of Behavioral Medicine. 2025-03-13 - Accounting for unmet needs resulting from cancer-related cognitive impairment.Darren Haywood, Alexandre Chan, Raymond J Chan, Evan Dauer, Haryana M Dhillon
Journal of Cancer Survivorship. 2025-03-11
Press Mentions
Sticking with CDK4/6 Inhibitors for Breast Cancer Wins in Post-Progression SettingDecember 20th, 2024- New Video: Navigating Breast Cancer Treatment OptionsOctober 11th, 2024
- 2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
- Join now to see all
Grant Support
- Dance-based Avenues to Advance Nonpharmacologic treatment of Chemotherapy Effects (DAANCE): a multicenter trialOHIO STATE UNIVERSITY2024–2029
- Prevention of paclitaxel-induced peripheral neuropathy with nilotinibOHIO STATE UNIVERSITY2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
